J Clin Lipidol. 2014 Jan-Feb;8(1):29-60. doi: 10.1016/j.jacl.2013.12.005. Epub 2013 Dec 17.
An international panel of the International Atherosclerosis Society has developed a new set of recommendations for the management of dyslipidemia. The panel identifies non--high-density lipoprotein cholesterol as the major atherogenic lipoprotein. Primary and secondary prevention are considered separately. Optimal levels for atherogenic lipoproteins are derived for the two forms of prevention. For primary prevention, the recommendations emphasize lifestyle therapies to reduce atherogenic lipoproteins; drug therapy is reserved for subjects at greater risk. Risk assessment is based on estimation of lifetime risk according to differences in baseline population risk in different nations or regions. Secondary prevention emphasizes use of cholesterol-lowering drugs to attain optimal levels of atherogenic lipoproteins.
国际动脉粥样硬化学会的一个国际专家小组制定了一套新的血脂异常管理建议。该小组将非高密度脂蛋白胆固醇确定为主要的致动脉粥样硬化脂蛋白。一级预防和二级预防分别进行考虑。针对这两种预防形式得出了致动脉粥样硬化脂蛋白的最佳水平。对于一级预防，建议强调采用生活方式疗法来降低致动脉粥样硬化脂蛋白；药物治疗则保留给风险更高的人群。风险评估基于根据不同国家或地区基线人群风险差异对终生风险的估计。二级预防强调使用降胆固醇药物以达到致动脉粥样硬化脂蛋白的最佳水平。
